Exogenous lactoferrin as an anti-inflammatory treatment for persistent breeding-induced endometritis (PBIE) in the horse - 2163
- *Abstract
-
Overview
Mares normally mount a temporary immune response during the breeding process. A subset of mares fails to resolve the inflammatory response, which leads to persistent breeding-induced endometritis (PBIE). PBIE interferes with conception and normal reproductive processes, which creates a large financial burden for the horse breeding industry.
Invention
Researchers at the University of Kentucky are developing a safe, inexpensive treatment for PBIE in breeding mares. Data indicate that intrauterine administration of 1mg/500kg human recombinant lactoferrin 6 hours after breeding decreases neutrophil numbers, decreases pro-inflammatory cytokines, and increases anti-inflammatory cytokines without negatively affecting vital signs. This treatment strategy provides horse breeders with an effective single-use biologic to prevent PBIE and improve reproductive success.
Applications
This invention is a safe and effective anti-inflammatory treatment for horses, which is specifically applicable to counteract PBIE in breeding mares.
Advantages
- One-dose treatment
- Inexpensive and effective modulator of inflammation
- A safe biologic compound
- In addition to anti-inflammatory effects, lactoferrin has been cited as bactericidal, anti-fungal, and tumor suppressant
Development Stage: Discovery and Early Development Research
Patent Status: Patent Pending
- 国家/地区
- 美国
